Km Biologics Co., Ltd.

Kumamoto University

Kagoshima University

Shino-Test Corporation

Alnylam Pharmaceuticals, Inc.

National University Corporation Kumamoto University

Yukio Ando

Dinah Wen-Yee Sah

Toshihiro Nakashima

Kenji Soejima

Masaharu Torikai

Hirofumi Higuchi

Ikuro Maruyama

Rene Alvarez

Hirofumi Jono

Yu Su

Akihiko Hosoi

Masayo Ueno

Tomoyo Takeo

Mineyuki Mizuguchi

Shingo Yamada

A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.

Anti-transthyretin human antibody

A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.

Anti-transthyretin humanized antibody

Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody

Growing community of inventors

Kumamoto, Japan

Yukio Ando